

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

ORAL SMALL-MOLECULE CDK INHIBITOR SYH2043 OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2043 (the “**Product**”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

SYH2043, an oral small-molecule CDK2/4/6 inhibitor, is a novel anti-tumor drug candidate with independent intellectual property rights. The Product demonstrated good anti-tumor effects in multiple solid tumor types in preclinical efficacy study, especially in breast cancer with intrinsic resistance and acquired resistance against CDK4/6 inhibitors. Preclinical pharmacokinetic and safety evaluation also demonstrated that the Product has good druggability and manageable safety profile. The Group will endeavor to advance the clinical development of the Product and strive to launch the Product as soon as possible.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 28 December 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.